NFE2L2 and neoplasm: More recently, the same group showed that high levels of CD44, the most common marker of CSC, led to p62-dependent NRF2 activation in breast CSC-like cells, promoting an aggressive phenotype with sustained tumor growth and increased drug resistance [223].